Home

Results 1 - 10 of 447,971 for solution. Search took 2.144 seconds.  
Sort by date/Sort by relevance
Although the Applicant doubts that this is a durable solution, this decision is a matter of policy which is in the sole discretion of the Organization. (...) The Guidelines provide that “once positions are approved for discontinuation…manager and staff should consult with DHRM to ensure that appropriate solutions are found for all affected personnel.” (...) He also lost the valuable opportunity to ensure an agreed employment solution to which he was le Decision 89. The Tribunal finds that: a.
Language:English
Score: 498429.44 - www.un.org/en/internalj...dt/judgments/undt-2016-084.pdf
Data Source: oaj
In her request for an extension of time the applicant specified that the reasons for the request were “the change of counsel and pursuit of informal solution”. 2. On 17 June 2010 the Tribunal granted the applicant until 23 July 2010 to file her application. 3. (...) As the effort of seeking informal solution is still [ongoing], filing the application at this time may not be conducive to the effort, even have some negative impact.
Language:English
Score: 471939.65 - www.un.org/en/internalj...dt/judgments/undt-2010-163.pdf
Data Source: oaj
In this is the case, the Administration will therefore need to find an alternative solution to ensuring that the deduction is not implemented before the Tribunal has issued its final determination of the pending suspension of action application. (...) UNDT/NY/2019/020 Order No. 50 (NY/2019) Page 5 of 5 technically feasible, the Administration shall use its best endeavors to find an alternative solution to ensure that the Applicant receives his full salary for March 2019. 13.
Language:English
Score: 452722.46 - www.un.org/en/internalj...t/orders/Order 2019-NY-050.pdf
Data Source: oaj
He concluded by expressing the hope that an acceptable solution to everyone could be found. 8. In an e-mail sent to Mr. (...) Sprauten stressed that he was open to finding an acceptable solution for everyone. He recalled that he had accepted the offer of employment with the exception of the start date. 10. (...) He never rejected the dates mentioned by the Appellant; he merely wished to explore solutions that would have better suited his family situation. 19.
Language:English
Score: 451152.44 - www.un.org/en/internalj...t/judgments/2011-unat-111e.pdf
Data Source: oaj
The Tribunal further notes that after the Applicant had shared her security concerns with OHCHR, the Office reviewed her reported information and offered several possible courses of action. These possible solutions were discussed with the Applicant from July 2018 until the end of her appointment in September 2018. 17. (...) It is evident from the record and undisputed that the Applicant declined both solutions presented by the Administration as she did not deem them appropriate. (...) He stresses that the Organization tried to find a solution to the Applicant’s situation while she could be traveled back as an employee of the United Nations with a valid passport and although the security risk had been assessed as low. 35.
Language:English
Score: 451152.44 - www.un.org/en/internalj...dt/judgments/undt-2021-044.pdf
Data Source: oaj
It would be difficult to propose a “one-size-fits-all solution” for this issue; however, there is need to consider, discuss, and find the best solution possible. (...) Taking into account developing experiences and new attempts in this regard, organizations should consider finding appropriate solutions. Organizations should, at least, consider establishing informal/voluntary/administrative internal dispute resolution mechanisms that can be used before resorting to formal external processes. 2 General Assembly resolutions 65/247, 63/250 and 61/244.
Language:English
Score: 437622.56 - www.un.org/en/internalj...dt/judgments/undt-2014-147.pdf
Data Source: oaj
Program Trade Name INN Pharmaceutical presentation and Strength LTA holder COPAXONE 40 Glatiramer acetate solution for injection in pre-filled syringe, 40 mg/ml, 1 ml Teva COPAXONE-TEVA Glatiramer acetate solution for injection in pre-filled syringe, 20 mg/ml, 1 ml Teva MYOZYME Alglucosidase alfa powder for concentrate for solution for infusion, 50 mg Genzyme FABRAZYME Agalsidase Beta powder for concentrate for solution for infusion, 35 mg Genzyme ORFADIN Nitisinone hard capsules, 2 mg Swedish Orphan Biovitrum ORFADIN Nitisinone hard capsules, 5 mg Swedish Orphan Biovitrum ORFADIN Nitisinone hard capsules, 10 mg Swedish Orphan Biovitrum Mucopolysaccharidoses ALDURAZYME Laronidase concentrate for solution for infusion in vial, 5 ml in vial, 100 IU/ ml Genzyme Gaucher CEREZYME Imiglucerase powder for concentrate for solution for infusion in vial, 400 U/ml Genzyme REFACTO Human coagulation factor VIII (recombinant) powder for solution for injection, 1000 IU Pfizer REFACTO Human coagulation factor VIII (recombinant) powder for solution for injection, 500 IU Pfizer REFACTO Human coagulation factor VIII (recombinant) powder for solution for injection, 250 IU Pfizer NOVOSEVEN Eptacog alfa activated (recombinant factor VIIa) powder for solution for injection in vial 2 mg, 100 KIU Novo Nordisk NOVOSEVEN Eptacog alfa activated (recombinant factor VIIa) powder for solution for injection in vial 5 mg, 250 KIU Novo Nordisk EMOCLOT Human coagulation factor VIII (plasma) lyophilizate for solution for infusion of 500 IU in vial Kedrion REFACTO Human coagulation factor VIII (recombinant) powder for solution for injection, 1000 IU Pfizer REFACTO Human coagulation factor VIII (recombinant) powder for solution for injection, 500 IU Pfizer NOVOSEVEN Eptacog alfa activated (recombinant factor VIIa) powder for solution for injection in vial 2 mg, 100 KIU Novo Nordisk NOVOSEVEN Eptacog alfa activated (recombinant factor VIIa) powder for solution for injection in vial 5 mg, 250 KIU Novo Nordisk EMOCLOT Human coagulation factor VIII (plasma) lyophilizate for solution for infusion of 500 IU in vial Kedrion Bleeding NOVOSEVEN Eptacog alfa activated (recombinant factor VIIa) powder for solution for injection in vial 5 mg, 250 KIU or 2 mg, 100 KIU Novo Nordisk HUMIRA Adalimumab solution for injection 40mg/0.8ml, in pre-filled syringe 0.8ml AbbVie HUMIRA Adalimumab solution for injection 40mg/0.8ml, in 0.8 ml vial for single use AbbVie Cystic Fibrosis COLOMYCIN Colistimethate Sodium powder for solution for injection, infusion or inhalation 2 000 000 IU in vial Teva Cerebral Palsy DYSPORT Botulinum toxin A powder for solution for injection 500U in vial Ipsen DIPHERELINE Triptorelin powder 11,25 mg and solution for suspension for injection for extended release action Ipsen ZAVEDOS Idarubicin lyophilizate for injection, 5 mg Pfizer CYTOSAR Cytarabine lyophilizate for injection, 1000 mg Pfizer CYTOSAR Cytarabine lyophilizate for injection, 100 mg Pfizer AROMASIN Exemestane sugar coated tablets, 25 mg Pfizer VINCRISTINE-TEVA Vincristine solution for injection, 1 mg/ml in vial of 1 ml Actavis DOXORUBICIN-TEVA Doxorubicin concentrate for solution for infusion, 2mg/ml in vial of 25 ml Actavis LEICOFOSIN Calcium folinate solution for injection, 10 mg/ml in vial of 3 ml Actavis METHOTREXATE-TEVA Methotrexate solution for injection, 25 mg/ml in vial of 2 ml Actavis METHOTREXATE-TEVA Methotrexate solution for injection, 100 mg/ml in vial of 10 ml Actavis IRYNOSYNDAN Irinotecan concentrate for solution for infusion 20 mg/ml in vial of 5 ml Actavis IRYNOSYNDAN Irinotecan concentrate for solution for infusion 20 mg/ml in vial of 15 ml Actavis EPIRUBICIN-TEVA Epirubicin solution for injection and infusion, 2 mg/ml in vial of 25 ml Actavis EPIRUBICIN-TEVA Epirubicin solution for injection and infusion, 2 mg/ml in vial of 5 ml Actavis BICALUTAMIDE-TEVA Bicalutamide film-coated tablets 50 mg Teva BICALUTAMIDE-TEVA Bicalutamide film-coated tablets 150 mg Teva LETROZOLE-TEVA Letrozole film-coated tablets 2.5 mg Teva ETOPOSID EBW Etoposide 200 mg, Concentrate for solution for infusion, 20 mg/ml in vial of 10 ml (200 mg) Sandoz ZARZIO Filgrastim 48 mln IU, Solution for injection, 48 mln IU in prefilled syringe of 0,5 ml Sandoz VINORELBIN EBW Vinorelbine 50 mg, Concentrate for solution for infusion, 10 mg/ml in vial of 5 ml (50 mg) Sandoz GEMCITABIN EBW Gemcitabine 200 mg, Concentrate for solution for infusion, 40 mg/ml in vial of 5 ml Sandoz GEMCITABIN EBW Gemcitabine 1000 mg, Concentrate for solution for infusion, 40 mg/ml in vial of 25 ml Sandoz DOXORUBICIN EBW Doxorubicin 50 mg, Concentrate for solution for infusion, 2 mg/ml in vial of 25 ml (50 mg) Sandoz DOXORUBICIN EBW Doxorubicin 100 mg, Concentrate for solution for infusion, 2 mg/ml in vial of 50 ml (100 mg) Sandoz DOCETAXEL EBW Docetaxel 20 mg, Concentrate for solution for infusion 10 mg/ml in vial of 2 ml (20 mg) Sandoz DOCETAXEL EBW Docetaxel 80 mg, Concentrate for solution for infusion 10 mg/ml in vial of 8 ml (80 mg) Sandoz ETOPOSID EBW Etoposide 100 mg, Concentrate for solution for infusion, 20 mg/ml in vial of 5 ml (100 mg) Sandoz OXALIPLATIN EBW Oxaliplatin 50 mg, Concentrate for solution for infusion, 5 mg/ml in vial of 10 ml, 1 vial per pack Sandoz OXALIPLATIN EBW Oxaliplatin 100 mg, Concentrate for solution for infusion, 5 mg/ml in vial of 20 ml Sandoz PACLITAXEL EBW Paclitaxel 100 mg, Concentrate for solution for infusion, 6 mg/ml in vial of 16,7 ml (100 mg) Sandoz 5-FU EBW / 5- FLUOROURACIL EBW Fluorouracil 500 mg, Concentrate for solution for infusion, 50 mg/ml in vial of 10 ml Sandoz CISPLATIN EBW Cisplatin 50 mg, Concentrate for solution for infusion 0,5 mg/ml in vial of 100 ml (50 mg) Sandoz CISPLATIN EBW Cisplatin 100 mg, Concentrate for solution for infusion 1 mg/ml in vial of 100 ml (100 mg) Sandoz PACLITAXEL EBW Paclitaxel 30 mg, Concentrate for solution for infusion, 6 mg/ml in vial of 5 ml (30 mg) Sandoz CARBOPLATIN EBW Carboplatin 150 mg, Concentrate for solution for infusion, 10 mg/ml in vial of 15 ml (150 mg) Sandoz CARBOPLATIN EBW Carboplatin 450 mg, Concentrate for solution for infusion, 10 mg/ml in vial of 45 ml (450 mg) Sandoz GRANOCYTE 34 Lenograstim 33,6 mln IU, Powder and solvent for solution for infusion Sanofi-Aventis ENDOXAN Cyclophosphamide powder for solution for injections 1000 mg Baxter ENDOXAN Cyclophosphamide powder for solution for injections 500 mg Baxter ENDOXAN Cyclophosphamide powder for solution for injections 200 mg Baxter ENDOXAN Cyclophosphamide sugar-coated tablets 50 mg Baxter UROMITEXAN Mesna solution for injections 100 mg/ml, 4 ml Baxter HOLOXAN Ifosfamide powder for solution for injections 1000 mg Baxter Dwarfism OMNITROPE Somatropin Solution for injection, 5mg/1.5ml, one cartridge contains 1.5 ml, #5 cartridges in a pack Sandoz ADVAGRAF Tacrolimus 0.5 mg, Extended release capsules Astellas ADVAGRAF Tacrolimus 1 mg, Extended release capsules Astellas ADVAGRAF Tacrolimus 3 mg, Extended release capsules Astellas ADVAGRAF Tacrolimus 5 mg, Extended release capsules Astellas EQUORAL Cyclosporine 25 mg, Soft capsules Teva List of UNDP Long-Term Agreements for medicines procurement in Ukraine Orphans Diseases Child Hemophilia Adult Hemophilia JRA Multiple Sclerosis Adult Onco Transplantology EQUORAL Cyclosporine 50 mg, Soft capsules Teva EQUORAL Cyclosporine 100 mg, Soft capsules Teva MYFENAX Mycophenolate mofetil 250 mg, Hard capsules Teva THYMOGLOBULINE Antithymocyte immunoglobulin (rabbit) Lyophilized powder for preparation of concentrate for solution for infusion 25 mg in vial Sanofi-Aventis Vylvio Ombitasvir, paritaprevir and ritonavir 12,5 mg/75,0 mg/50,0 mg, film-coated tablets AbbVie Vyrelakir Dasabuvir 250 mg, film-coated tablets AbbVie MYCAMINE Micafungin 100 mg, powder for solution for infusion Astellas MYCAMINE Micafungin 50 mg, powder for solution for infusion Astellas Equoral Cyclosporine 25 mg, Soft capsules Teva Equoral Cyclosporine 50 mg, Soft capsules Teva Equoral Cyclosporine 100 mg, Soft capsules Teva Colomycin injection Colisthimethate sodium 2 000 000 IU, powder for solution for injection Teva Carboplatin Carboplatin 50 mg, concentrate for solution for infusion Teva Etoposide-Teva Etoposide 200 mg, concentrate for solution for infusion Teva Doxorubicin-Teva Doxorubicin 10 mg, concentrate for solution for infusion Teva Targocid Teicoplanin 400 mg, lyophilizates for solution for injection in complex with solution Sanofi-Aventis Thymoglobulin Antithymocyte immunoglobulin (rabbit) 25 mg, Lyophilized powder for preparation of concentrate for solution for infusion Sanofi-Aventis RITUXIM Rituximab concentrate for solution for infusion, 100 mg/10 ml, 10 ml in a vial Lumier Pharma RITUXIM Rituximab concentrate for solution for infusion, 500 mg/50 ml, 50 ml in vial Lumier Pharma BLEOCIN-C Bleomicyn lyophilizate for solution for injection, 15 000 IU in vial Lumier Pharma Viral hepatitis Child Onco Transplantology LTAs database
Language:English
Score: 429323.2 - https://www.undp.org/sites/g/f...35a655137330efad97f3e6cffe.pdf
Data Source: un
Badabon Sangho Where : Bangladesh Area of Solutions : Biodiversity and nature-based solutions; Sustainable cities and communities; Education and advocacy; Ocean and life... (...) High Atlas Foundation Where : Morocco  Solutions : Biodiversity and nature-based solutions, Sustainable cities and communities, Involvement of local communities and... (...) Where : Antipolo and Laguna, Philippines  Solutions : Biodiversity and nature-based solutions, Disaster preparedness and risk mitigation, Women and...
Language:English
Score: 429170.6 - https://www.un.org/en/civil-so...society-climate-action-stories
Data Source: un
Badabon Sangho Where : Bangladesh Area of Solutions : Biodiversity and nature-based solutions; Sustainable cities and communities; Education and advocacy; Ocean and life... (...) High Atlas Foundation Where : Morocco  Solutions : Biodiversity and nature-based solutions, Sustainable cities and communities, Involvement of local communities and... (...) Where : Antipolo and Laguna, Philippines  Solutions : Biodiversity and nature-based solutions, Disaster preparedness and risk mitigation, Women and...
Language:English
Score: 429170.6 - https://www.un.org/collection/54315/13350
Data Source: un
Delaunay claimed did not allow her to be fully compensated for the prejudice she had suffered and the alleged inability of the ICJ to find a common solution with the UNJSPF, Ms. Delaunay informed the ICJ Registrar by e-mail dated 3 October 2016 that she wished to pursue her request for compensation against the ICJ submitted on 1 February 2016. (...) Having considered the record as well as the parties’ submissions, we find that the appropriate solution at this point is for Ms. Delaunay to file a request before the Pension Fund to review the decision to convert her six years and eight months 25 per cent part-time employment into one year and eight months full-time employment in accordance with Section K of the Administrative Rules of the UNJSPF.
Language:English
Score: 427834.9 - www.un.org/en/internalj...rders/order-unat-2017-301E.pdf
Data Source: oaj